BeStock  
Stocks › CGON

CG Oncology CGON

US equityMarket cap rank #1717
$79.47 −$2.43 (-2.97%)
Market closed · Nov 22, 5:50 am ET · Last extended-hours $79.50 +0.04%
Open$80.32
Prev close$81.90
Day range$79.21 – $83.16
Volume1.67M
Market cap$7.10B
P/E (TTM)–
Dividend yield–
Founded2010
CEOMr. Arthur Kuan
Employees142
HeadquartersDallas, United States of America
Websitewww.cgoncology.com

Revenue per employee

$1,336$11.0K$20.8K$30.5KDec '23Dec '24Dec '25

142 employees as of 2025/FY (+25.7% YoY). Revenue per employee is total revenue divided by headcount — a rough productivity gauge, not a per-worker pay figure.

Management team

Arthur Kuan Chairman of the Board, President and Chief Executive Officer
Age 35 · Total comp. $11,928,401.00 · As of 25 May 2026
Background

Arthur Kuan has served as our Chief Executive Officer and as a member of our Board since our inception in 2017, and as Chairman since December 2023. As a Founding Member of Ally Bridge Group, a global healthcare-focused investment platform, Mr. Kuan played a role in managing the fund's portfolio companies from January 2013 to July 2015. Mr. Kuan also served on the IP Commercialization Strategy Committee at Moffitt Cancer Center from November 2017 to January 2024. Previously, Mr. Kuan was a member of Themes Investment Partners, a Private Equity fund based in Hong Kong, where he played a central role in coordinating cross-border technology transfer and regulatory submissions for portfolio companies. Mr. Kuan began his career in an operational role at Dinova Capital, a Shanghai-based, medical technology incubator fund, evaluating medical device investment opportunities. Mr. Kuan has served on the board of directors of Chunghwa Chemical Synthesis & Biotech (TPEX: 1762), a Taiwanese manufacturer and distributor of chemical synthetic products and biotechnology products, since 2022, where he serves on its compensation committee and audit committee. From 2016 to 2023, he served on the board of directors of Allied Industrial Corp., Ltd. (TPEX: 4702), a leading supplier of disperse dyestuff. Mr. Kuan received his M.S. in Biotechnology from Johns Hopkins University and his B.A. in Biology from University of Pennsylvania. On May 20, 2026, the Company's Board of Directors also approved the appointment of Arthur Kuan as President of the Company.

Dr. Vijay Kasturi, M.D. Chief Medical Officer
Age 58 · Total comp. $3,599,946.00 · As of 23 Apr 2026
Background

Vijay Kasturi has served as our Chief Medical Officer since August 2023. Previously, Dr. Kasturi was Vice President of Clinical Development and Medical Affairs at AVEO Pharmaceuticals, a cancer therapeutics company, from April 2021 to August 2023. Prior to that, he was Senior Vice President of Scientific Affairs at FerGene from March 2020 to March 2021. Prior to joining FerGene, Dr. Kasturi was Head of U.S. Medical Affairs, Oncology for EMD Serono, a pharmaceutical company focused on reproductive health, multiple sclerosis and cancer, from November 2015 to March 2020, where he had responsibility for developing global and regional strategies that brought new therapies to patients in immunology, hematology and oncology. Earlier in his career, Dr. Kasturi treated patients with cancer and served as an assistant professor of medicine, Division of Hematology-Oncology at the University of Massachusetts Medical School and as the program leader for genitourinary oncology at UMass Memorial Cancer Center. Dr. Kasturi trained in Hematology-Oncology at the National Cancer Institute and worked as an investigator and physician at the National Cancer Institute and Dartmouth Hitchcock Medical Center. Dr. Kasturi holds an M.D. from Rush Medical College of Rush University and a B.S. in Biology from University of Illinois, Chicago.

Joshua F. Patterson Secretary, General Counsel and Chief Compliance Officer
Total comp. $2,364,380.00 · As of 12 Apr 2026
Background

Josh Patterson serves as General Counsel & Chief Compliance Officer at CG Oncology and has more than 20 years of experience serving as in-house counsel in the biopharmaceutical industry. Prior to joining CG Oncology, Josh served as General Counsel & Chief Compliance Officer at GamidaCell Ltd. where he was responsible for providing strategic legal advice and counsel to the board of directors and the executive leadership team, as well as management of the global legal and compliance functions. Prior to GamidaCell, Josh served as General Counsel of AkceaTherapeutics, Inc. where he was responsible for Akcea'sglobal legal matters and strategic transactions. Prior to joining Akcea, Josh was Deputy General Counsel at Ionis Pharmaceuticals, Inc., where he specialized in licensing and other strategic transactions. He also previously served as in-house counsel at Amylin Pharmaceuticals, Inc., where he was responsible for general corporate transactions, clinical trials and privacy matters. Josh received his B.S. in history from Carthage College and his J.D. from the Syracuse University College of Law.

Christina Rossi, M.B.A. Independent Director
Age 50 · Total comp. $575,151.00 · As of 23 Apr 2026
Background

Christina Rossi has served as a member of our Board since November 2025. Ms. Rossi has more than 25 years of global pharmaceutical and biotechnology experience. Ms. Rossi served as the Interim Chief Executive Officer from July 2025 to September 2025 and as the Chief Operating Officer of Blueprint Medicines (Nasdaq: BPMC) from 2022 until its acquisition by Sanofi in July 2025. Previously, Ms. Rossi served as Chief Commercial Officer from October 2018 to April 2022 and had overseen the commercial launches of Blueprint Medicines' therapies across multiple indications and geographies, including the creation of commercial infrastructure and successful market access efforts in the U.S. and Europe. Prior to joining Blueprint Medicines, Ms. Rossi served as the Multiple Sclerosis Business Unit Head, North America, at Sanofi Genzyme. In this role, Ms. Rossi oversaw all aspects of the financial performance of Sanofi Genzyme's MS franchise and increased market share for existing products, led the launch of new therapies and optimized operations to accelerate patient access. Previously, Ms. Rossi served as Vice President, MS Sales, and Vice President, MS Patient and Provider Services, at Sanofi Genzyme. Prior to joining Sanofi Genzyme, Ms. Rossi held various roles at Biogen Inc., including Head, Commercial Strategy for Eidetica Biopharma GmbH, Biogen's biosimilar-focused venture, and U.S. Brand Leader for TYSABRI (natalizumab). In addition, Ms. Rossi consulted in the healthcare practice at the Boston Consulting Group. Ms. Rossi serves as an independent director on the board of Xilio Therapeutics, Inc. (Nasdaq: XLO), where she chairs the compensation committee. Ms. Rossi holds a B.S. in biology from Duke University and an M.B.A. from Harvard Business School.

Dr. Leonard E. Post, PhD Lead Independent Director
Age 73 · Total comp. $500,127.00 · As of 23 Apr 2026
Background

Leonard Post, Ph.D. has served as a member of our Board since 2018 and as our lead independent director since 2024. Dr. Post has over three decades of pharmaceutical R&D experience. From July 2016 to January 2024, Dr. Post served as Chief Scientific Officer of Vivace Therapeutics, an oncology company working on small molecules targeting the hippo pathway, and from October 2018 to January 2024 served as Chief Scientific Officer of its sister company Virtuoso Therapeutics, a company working on bispecific antibodies for oncology. From February 2010 until June 2016, Dr. Post worked at BioMarin, in various positions including Chief Scientific Officer. During that time, he oversaw the initiation of BioMarin's first gene therapy project for hemophilia A. Prior to that, Dr. Post served as Chief Scientific Officer of LEAD Therapeutics, Senior Vice President of Research & Development at Onyx Pharmaceuticals, and Vice President of Discovery Research at Parke-Davis Pharmaceuticals. Dr. Post is also currently an advisor to Canaan Partners. Dr. Post has served on the board of directors of publicly-traded biopharmaceutical company uniQure N.V. (Nasdaq: QURE) since June 2020, where he serves as chair of its research and development committee, and privately-held companies, Orphagen Pharmaceuticals, Inc., Fedora Pharma, Inc., ImmvirX, ML Biosolutions, Grace Science LLC and Acelink Therapeutics. Dr. Post also previously served on the board of directors of publicly-traded Fulgent Genetics, Inc. (Nasdaq: FLGT) from August 2022 to October 2022. Dr. Post is a virologist by training and did early work on engineering of herpes simplex virus as a postdoctoral fellow. He has a Bachelor of Science degree in Chemistry from University of Michigan, and a Ph.D. in Biochemistry from University of Wisconsin.

Susan E. Graf Independent Director
Age 53 · Total comp. $482,627.00 · As of 23 Apr 2026
Background

Susan Graf, R.Ph., M.B.A., has served as a member of our Board since November 2023. Ms. Graf has served as a Senior Advisor and Entrepreneur in Residence at Locust Walk Partners, LLC, a global life science transaction firm, since May 2021. Ms. Graf previously served as Chief Executive Officer of biotechnology company Akamara Therapeutics from August 2019 to May 2021. Prior to Akamara Therapeutics, Ms. Graf was Chief Business Officer at Epizyme, a biopharmaceutical company, from April 2016 to September 2018, where she also served as Principal Financial Officer from August 2017 to September 2018. Prior to Epizyme, Ms. Graf held the position of Vice President, Corporate Development and Strategy for NPS Pharma before it was acquired by Shire in 2015. Earlier in her career, Ms. Graf spent nearly 18 years at Roche in a number of leadership and executive positions. Ms. Graf chaired the audit committee of Finch Therapeutics, a publicly-traded microbiome therapeutics company, from April 2021 through March 2024 and served as Board Chair from April 2022 through March 2024. Since November 2024 Ms. Graf has also chaired the audit committee of Aardvark Therapeutics (Nasdaq: AARD), a publicly-traded metabolic disease company, and since December 2021 she has served on the board of directors of Kaleo, a privately held pharmaceutical company. Ms. Graf has an M.B.A. from the Stern School of Business at New York University and a B.Pharm. from Purdue University.

Dr. Brian Liu, M.D. Independent Director
Age 37 · Total comp. $475,127.00 · As of 23 Apr 2026
Background

Brian Liu, M.D. has served as a member of our Board since September 2022. Dr. Liu serves as Managing Member at Seven Fleet Capital since May 2025. Dr. Liu is a Managing Director at Longitude Capital Management Co., LLC (Longitude Capital), a healthcare venture capital firm, where he has been employed since 2018. Prior to joining Longitude Capital, Dr. Liu was an Engagement Manager in the pharmaceuticals practice of McKinsey & Company from January 2016 to July 2018. Dr. Liu has served on the board of directors of Alentis Therapeutics AG since November 2024, Helicore Biopharma, Inc. since January 2024, and Lassen Therapeutics, Inc. since August 2023. He has also served as a board observer at Quanta Therapeutics Inc. since October 2020. He previously served as a board observer at Endeavor Biomedicines Inc., Inflazome Ltd. (acquired by Roche Holding AG), Rivus Pharmaceuticals, Inc., Talaris Therapeutics, Inc., Vera Therapeutics, Inc., and Zenas Biopharma, Inc. Dr. Liu holds an M.D. from Stanford University School of Medicine and a B.S. in Biomedical Engineering from Johns Hopkins University.

Victor Tong, Jr Independent Director
Age 42 · Total comp. $467,627.00 · As of 23 Apr 2026
Background

Victor Tong, Jr. has served as a member of our Board since July 2023. Mr. Tong is a Managing Director at Decheng Capital (Decheng), an investment firm, where he has worked since its inception in 2012 and focuses on investments in biotechnology and medical technology companies in China and the United States. Before joining Decheng, Mr. Tong was a Principal at Bay City Capital, a life sciences investment firm, and a member of the healthcare investment banking division at Morgan Stanley. Mr. Tong has served on the board of publicly-traded company Aardvark Therapeutics, Inc. since May 2024. He also serves on the board of directors of multiple privately held biotechnology and biopharmaceutical companies including Cellares Corp., Harton Therapeutics, Hummingbird Bioscience, LevitasBio, Baylor Genetics, Take2 and Watchmaker Genomics. Mr. Tong holds a B.A. in Molecular and Cell Biology and B.S. in Business Administration from University of California, Berkeley.

Dr. James J. Mule Independent Director
Age 73 · Total comp. $457,627.00 · As of 23 Apr 2026
Background

James J. Mule, Ph.D. has served as a member of our board of directors since 2018. Dr. Mule has served as Associate Center Director for Translational Science and the Michael McGillicuddy (U.S. Senator Connie Mack (ret.) & Family) Endowed Chair for Melanoma Research and Treatment and is the Associate Center Director of the Moffitt Cancer Center, Tampa, Florida, where he has served as a Director since 2003. Since 1993, Dr. Mule has served multiple tenures as a special government employee to the Food and Drug Administration (FDA) at the Center for Drug Evaluation and Research and at the Center for Biologics Evaluation and Research and to the National Cancer Institute (NCI). Dr. Mule also served on the board of directors of publicly-traded company Fulgent Genetics, Inc. (Nasdaq: FLGT) from 2016 to 2020. Dr. Mule serves on the advisory boards of numerous biotechnology companies, pharmaceutical companies, NCI-designated cancer centers and investment funds, including Buffett Cancer Center, Omaha; Masonic Cancer Center, Minneapolis; Affyimmune Therapeutics; Aleta Biotherapeutics; OncoPep; Turnstone Biologics; UbiVac; Vault Pharma; Vycellix; and Noble Life Science Partners. Dr. Mule holds an Interdisciplinary Ph.D. in Tumor Immunology, Immunocytology, and Immunopathology from University of Washington and Fred Hutchinson Cancer Research Center, Seattle, Washington, a M.S. in Cellular Immunology from University of Washington School of Medicine and a B.A. from New Jersey City University. Dr. Mule received his formal postgraduate training at the Surgery Branch, Division of Cancer Treatment, NCI, National Institutes of Health (NIH), Bethesda, Maryland. Dr. Mule has held tenured senior positions at the NCI/NIH and the University of Michigan, Ann Arbor.

James M. DeTore Chief Financial Officer and Principal Accounting Officer
Age 61 · Total comp. $96,000.00 · As of 12 Apr 2026
Background

Mr. DeTore has served as our Interim Principal Financial and Accounting Officer since November 2025 pursuant to a consulting agreement with Monomoy Advisors, LLC, and has been responsible for the Company's financial and accounting functions. Prior to joining the Company, from June 2021 to June 2025, Mr. DeTore was Chief Financial Officer at Neurogastrx, Inc. Prior to serving at Neurogastrx, from March 2017 to May 2021, Mr. DeTore was an independent consultant providing chief financial officer services to a variety of early and mid-stage biotechnology and pharmaceutical companies, and from August 2016 to February 2017, Mr. DeTore was with Proteostasis Therapeutics, serving as Chief Financial Officer. In addition, from November 2014 to February 2016, Mr. DeTore served as Chief Financial Officer at Bluebird Bio, Inc. Mr. DeTore holds a Bachelor of Science degree and a Master of Business Administration degree from Northeastern University. On April 13, 2026, CG Oncology, Inc. appointed Jim DeTore as the Company's Chief Financial Officer.

From SEC filings, via Futu. Compensation is total reported pay for the most recent fiscal year on file, not base salary alone.

Discussion

No comments yet — be the first to weigh in on CGON.

Sign in to join the discussion.

Scroll to Top